Introduction
The role of inflammation in asthma is now well recognized, and corticosteroids are being used increasingly in its treatment. However, frequent high-dose courses of oral steroids result in many side-effects including loss of bone mass, which can eventually lead to osteoporosis and fractures (1) . Several mechanisms may be involved in this process (2) (3) (4) (5) (Fig. 1) . Inhaled steroids have a wider therapeutic margin than oral steroids as a result of their high topical: systemic potency ratio, low bioavailability and high systemic clearance (2) . It is now recommended that regular inhaled steroids are started earlier in the course of asthma and that high doses are used initially to attain control of the disease (6), but there is still some concern that the amount absorbed might be sufficient to cause systemic side-effects.
The effect of high-dose inhaled corticosteroids on bone has been investigated in healthy adult volunteers and asthma patients of various ages. This review summarizes the data on beclomethasone dipropionate (BDP) and budesonide, the two most widely used inhaled steroids in the U.K.
Experience in Adults HEALTHY VOLUNTEERS
Non-comparative studies Studies in healthy adult volunteers have investigated the effects of high-dose inhaled corticosteroids on bone turnover using serum and urinary levels of various markers of bone metabolism, including hormones, enzymes and bone constituents. Noncomparative and placebo-controlled studies in Correspondence should be addressed to: M. D'Souza, Royal Brompton National Heart & Lung Institute, The Unit of General Practice, 1 Elm Road, Kingston upon Thomes, Surrey KT2 6HR, U.K. This supplement was sponsored by Glaxo Wellcome plc. subjects receiving high-dose BDP or budesonide for periods of 1 week to 1 month have generally found a reduction in serum osteocalcin levels, which has been interpreted as indicating reduced bone formation by osteoblasts (Table 1 ) (7) (8) (9) (10) (11) (12) (13) (14) (15) . This reduction is reversible; levels have been shown to return to baseline within 1 week of ceasing treatment with BDP 2000 pg daily (13). A placebo-controlled, cross-over study in 16 volunteers receiving BDP 400-2000 pg daily for 10 days attempted to define the threshold dose at which bone is affected (14) . A dose-dependent fall in serum osteocalcin levels was observed with BDP doses up to 1400 pg daily, at which the response reached a plateau. A study comparing oral prednisolone 15 mg daily with inhaled BDP 1000 pg daily reported a decrease in serum osteocalcin with both treatments, but the decrease was greater in volunteers receiving prednisolone (10) . In contrast, Peretz and Bourboux (12) detected no significant changes in serum osteocalcin, or any of the biochemical markers measured, in volunteers receiving inhaled BDP 1000 pg daily for 1 week.
Toogood et al. (15) found that inhaled budesonide 1200 or 2400 pg daily for 1 month reduced serum osteocalcin levels but did not alter urinary calcium or hydroxyproline output. Two further randomized, double-blind studies comparing the effects of inhaled budesonide and oral prednisolone reported similar results. In the first study (8, 9) , increasing doses of budesonide or prednisolone over a period of 3 weeks caused significant reductions in serum osteocalcin levels, but other serum and urinary markers remained unchanged. In the second study (7), 40 subjects received either high-or low-dose oral prednisolone or inhaled budesonide for 2 weeks while 10 control subjects received placebo. Serum osteocalcin levels were significantly reduced from baseline in a dosedependent manner during the first week of steroid therapy in both treatment arms, with there being no significant difference between treatments. No effect on urinary calcium or hydroxyproline was seen during budesonide treatment, in contrast to increases in these parameters with high-dose prednisolone.
Nadeau et al. (11) found no effects of budesonide (at doses up to 2400 l.rg daily for 14 days) on intestinal calcium absorption, serum calcium, phosphate and PTH levels.
Comparative studies Four studies have directly compared the effects of BDP and budesonide on bone metabolism in healthy volunteers, and these are summarized in Table 2 (1619). Brown et al. (17) measured plasma osteocalcin following inhalation of BDP or budesonide 2000 pg daily from metered dose inhalers (MDIs) with or without a spacer on six separate study days. There were no significant changes in plasma osteocalcin following budesonide, with or without a spacer; BDP reduced plasma osteocalcin at 24 h when inhaled without a spacer, but not when a spacer was used. In contrast, in another study BDP 2000 lrg daily for 4 weeks via an MD1 plus spacer produced a statistically significant increase in the urinary hydroxyproline:creatinine ratio and a fall in serum alkaline phosphatase (16) . However, values for both of these parameters remained within the normal ranges during treatment, and hence the clinical significance of these changes is uncertain. In addition, this study also found that in healthy volunteers inhaling budesonide 1800 pg daily through a spacer for 4 weeks there were no significant changes for any of these markers (16) .
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Jennings et al. (18) compared budesonide and BDP, both at doses of 800 pg daily increasing to 2500 pg daily, over 4 weeks. Serum osteocalcin and alkaline phosphatase levels fell during both treatments, but the reduction was significantly greater for those receiving BDP. The increase in urinary hydroxyproline:creatinine ratio observed following steroid treatment was also significantly greater with BDP Both drugs produced an increase in serum phosphate, but serum and urinary calcium remained stable. In a randomized, double-blind comparison of BDP 1000 or 2000 ng daily and budesonide 800 or 1600 l.rg daily, subjects received each treatment for 1 week at the lower dose and then 1 week at the higher dose (19) . At the lower doses, neither drug had an appreciable effect on serum osteocalcin. However, BDP 2000 l.rg daily produced a significant reduction in serum osteocalcin levels, which was not observed after budesonide 1600 pg daily.
The results of all volunteer studies in healthy volunteers indicate that both high-dose inhaled BDP and budesonide can impair bone metabolism but that inhaled steroids, even when used at very high doses, have considerably less effect than oral steroids. In addition, budesonide appears to have less effect than BDP on bone turnover indices (particularly osteocalcin) at clinically relevant doses. However, these results have to be interpreted with caution as the response to steroids in healthy subjects may be different from that in asthma patients, and asthma itself may have an effect on bone metabolism. Effects on bone in asthma patients are therefore difficult to predict from volunteer studies. In addition, all these studies used small subject groups that lacked statistical power, while several were uncontrolled (10, 11, 13) and/or included doses higher than those used in clinical practice (7) (8) (9) 11, 15) . One study included patients in both treatment arms without a formal cross-over design, which might have confounded the results (16) . Furthermore, all of these studies examined the effects of the two steroids on bone metabolism for periods of less than 1 month. Such short-term effects may be at least partially compensated over time and do not necessarily translate into osteoporosis in the long term (20) . A further problem was that no absolute baseline values were given in some studies (14,lS) and it is difficult to assess, therefore, whether the statistically significant changes found are of clinical relevance.
ASTHMA PATIENTS
Studies in asthma patients have investigated the effects of high-dose inhaled corticosteroids on bone density and bone turnover (Tables 3 and 4 No effect on urinary Ca or hydroxyproline with budesonide.
Decreased osteocalcin in both groups (PRED > BUD).
No effect on serum AP, serum and urinary Ca, or urinary hydroxyproline. Decreased osteocalcin in both groups. (21) compared the effects of high-dose BDP or budesonide (2800 ug daily) taken for at least 18 months with those of low doses (~500 ug daily) in matched groups of patients with low oral steroid usage over the previous 2 yr. Serum osteocalcin was lower and urinary phosphate higher in patients using highdose inhaled steroids, but there were no significant differences in the bone density of the lumbar spine and hip or markers of bone metabolism between low-and high-dose groups. In addition, there were no significant differences in bone density or osteocalcin levels between patients receiving BDP and budesonide, although this study was not designed to compare differences between the individual agents. A further study in patients who had taken a mean dose of 1323 p.g daily of BDP or budesonide for a median of 2 yr also found significantly reduced osteocalcin levels compared with age-and sex-matched patients receiving bronchodilators only (22) . The mean density of the femoral neck of these patients was significantly reduced in the steroid-treated group and was below the normal clinical range; however, there was no significant difference in this parameter between steroidtreated patients and those receiving bronchodilators alone, possibly suggesting it might be disease related. Mean bone density in the lumbar spine and Ward's triangle of the femur remained within the expected clinical range in both treatment groups.
Four studies have reported the effects of oral and inhaled steroids on bone turnover and density. Luengo et al. (24) observed no differences in calcium absorption or PTH serum levels between steroid-dependent patients treated with inhaled BDP (400-1600 ug daily) or oral steroids for a mean of 6.7 yr, and age-and sexmatched healthy volunteers. In a second study, Luengo et al. (25) compared changes in bone mass over 2 yr in 21 patients on oral steroids (mean 12 mg daily), 21 on inhaled BDP (100-900 ug dailyband 875 control subjects. The rate of bone loss for patients on oral steroids was higher than in control subjects, whereas there was no difference in this parameter between those on inhaled steroids and controls. Wolff et al. (28) reported a dose-response relationship between cumulative oral steroid dose and bone loss in five patients receiving an average of 12.5 mg daily oral prednisolone or equivalent for l-10 yr, but there was no evidence of reduced bone density in five patients who had received inhaled steroids (average dose 326 ug daily BDP or equivalent) for a similar period. Packe et al. (26) compared 17 patients with mild asthma who were steroid naive, 20 on inhaled BDP (1000-2000 ug daily for >l yr) and 20 on inhaled steroids plus continuous low-dose oral steroids. Bone,densities were significantly reduced with both oral and inhaled therapy, but the levels of markers of bone turnover in serum and urine remained unchanged.
Packe et al. (26) measured trabecular VBD in patients who had received inhaled budesonide (median dose 800 ug daily) for >l yr. VBD values for these patients were compared, retrospectively, with those from patients of an earlier study (26) who had used BDP (median dosage 1000 ug daily) for >l yr and patients who were steroid naive. Budesonide and BDP patients were matched for age, level of activity and asthma severity. VBD was significantly lower in both the budesonide and the BDP groups than in untreated patients. There was no significant difference in VBD between the BDP and budesonide patients, even when the budesonide results were adjusted to take into account the significant difference in dosage. Moreover, no significant differences in serum or urinary markers of bone turnover were observed between the three groups.
Comparative studies
In a pilot study to validate two novel markers of bone turnover, Kerstjens et al. (23) measured serum alkaline phosphatase, osteocalcin and PICP levels as markers of bone formation, together with the urinary hydroxyproline:creatinine ratio and serum ICTP levels as markers of bone resorption, in patients receiving budesonide or BDP 2800 ug daily. In both treatment groups osteocalcin levels decreased significantly while PICP levels and the PICP:ICTP ratio increased significantly after 4 weeks of treatment. There were no significant differences in serum osteocalcin, PICP or ICTP between groups receiving budesonide or BDP Morrison et al. (29) detected no changes in the urinary hydroxyproline:creatinine or calcium:creatinine ratios or serum alkaline phosphatase in patients with chronic obstructive airways disease treated with BDP or budesonide 2000 pg daily in a placebo-controlled cross-over trial. However, significant reductions were observed in both treatment groups in the urinary pyridinoline:creatinine and deoxypyridinoline:creatinine ratios, indicating reduced bone resorption. Serum osteocalcin levels fell by 26% with budesonide and 18% with BDP but, because a significant period effect was apparent and baseline osteocalcin levels were significantly different between treatments, there is no significant difference between the two steroids. These studies in asthma patients generally confirmed the effects of inhaled corticosteroids on markers of bone turnover observed in healthy volunteers. However, bone density studies, although conducted using accurate, modern techniques, show conflicting results. While these studies were conducted over longer periods of time, in larger groups of patients and at more clinically relevant doses than the volunteer studies, many were retrospective or crosssectional and could not evaluate progressive changes over time. In addition, most patients had previously taken oral corticosteroids, and the possible impact of this on bone could not be assessed.
POST-MENOPAUSAL WOMEN
Loss of bone mass occurs as a natural consequence of ageing. It may begin as early as the third decade in women and accelerates after the menopause when the protective effect of oestrogen is lost (30, 31) . Hence, any additional bone loss caused by corticosteroid treatment is an obvious cause for concern in this group of patients already at increased risk of osteoporosis.
Puolijoki et al. (32) assessed bone metabolism in nine post-menopausal women with asthma receiving BDP 200, 1000 or 2000 pg daily via a spacer for 3 weeks. Serum osteocalcin was significantly reduced throughout the 9-week follow-up period, but there were no significant alterations in other serum or urinary markers of bone turnover (Table 5 ). Stead et al. (32) investigated bone mineral density in a cross-sectional study in 11 asthmatic women aged 36-73 years, most of whom were post-menopausal. Ten had received BDP or budesonide 750-2000 pg daily for I-IO yr, and one had received both drugs. Lumbar spine bone density was reduced by 13% in these patients compared with healthy age-matched controls, but there was no evidence of active, rapid bone loss (Table 5 ). It is possible that previous oral corticosteroid therapy may have played a role in reducing bone mass in these patients.
Experience in Children
The impact of inhaled corticosteroids on bone formation is a particularly important aspect of treatment in children since they are actively growing. Studies in the patient population are summarized in Table 5 (34) (35) (36) (37) (38) .
Two studies reported no significant differences in bone mineralization or density between asthmatic children receiving BDP 300-800 pg daily for 6-25 months and age-matched controls (34, 37) ; serum osteocalcin was also unaffected (37). Priftis et al. (38) studied the effect of long-term use of inhaled BDP on biochemical markers of bone turnover and bone mineral content in 33 asthmatic children (median age 10 years) treated with BDP 180-790 pg m-2 day-l for 6-48 (mean 11.5) months. A dose-dependent, but not time-dependent, decrease in serum osteocalcin was demonstrated and the urinary calcium:creatinine ratio was elevated. No effects on markers of bone resorption were observed, but there was a reduction in bone mineralization that was independent of both dose and time.
Doull et al. (36) found no significant differences in baseline or three-monthly serum osteocalcin and urinary hydroxyproline measurements in 94 children receiving either BDP 200 ug twice daily by dry powder inhalation or placebo for 6 months in a randomized, double-blind trial. In contrast, an open, cross-over study during which 13 pre-pubertal children received BDP 800 pg daily via a Diskhaler@ and budesonide 800 pg daily via a TurbohalerB for 14 days found significantly reduced levels of PICP, the amino terminal of type III collagen, together with decreased urinary pyridinoline and deoxypyridinoline cross-links; this indicates suppression of bone and collagen turnover. This suppression was more apparent with BDP. Osteocalcin levels were not affected by either treatment (35) .
These results suggest that continuous treatment with BDP 1800 ug daily does not affect bone density in children. A reduction in bone and collagen turnover observed was with both budesonide and BDP at these doses, with the effect of budesonide being slightly less than that of BDP
Considerations
The threshold dose at which systemic side-effects appear with inhaled BDP in adults is believed to be approximately 1000 l.tg daily (39) . However, results have varied considerably between studies, with some studies in adults reporting no effects on bone turnover indices or bone mass with BDP 11000 yg daily (12, 19, (23) (24) (25) while others found effects on osteocaltin at BDP doses of < 1000 pg daily (10, 14) or budesonide doses of 800-1200 pg daily (7) (8) (9) 15) . Thus, the threshold dose for the effects of inhaled steroids on bone cannot clearly be defined.
The difference in effects on markers of bone turnover may reflect the sensitivities of these indicators. Osteocalcin is a bone matrix protein that is released by osteoblasts and widely regarded as a sensitive marker of bone formation. However, it can also be released during resorption (40) and attracts osteoclasts (41) . The clinical significance of osteocalcin suppression remains unknown and it may be most useful when used in conjunction with other markers. Changes in levels of collagen-related proteins, such as PICP and ICTP, mirror those of osteocalcin (23) , but collagen is not specific to bone. Increased blood and/or urinary levels of calcium, phosphate and hydroxyproline indicate bone resorption, but there are concerns over the sensitivity and specificity of these markers (42) . Studies relying on these measurements (11, 16, 24) may not have the sensitivity to detect small changes from baseline or differences between treatments. Short-term steroid-induced bone loss may be compensated over time by mechanisms that restore the equilibrium between bone formation and resorption but which cannot replace the deficit in bone mass. This might explain the reduction in bone density but normal levels of markers of bone turnover observed in some studies (27) . Conversely, several other studies (21, 25, 37) found that, although markers of bone turnover were altered after long-term use of high-dose inhaled steroids, bone density was not significantly reduced. Thus, abnormal serum or urinary marker levels do not necessarily mean later bone weakness or increased risk of fracture. Genetic factors, bone density before beginning treatment, activity levels, diet and hormonal status are also important determinants of bone loss. It may, therefore, be that certain groups of patients are more susceptible to clinically important bone loss during steroid treatment than others.
A final important consideration is inhaler design. Systemic absorption of inhaled corticosteroids can be a problem with pressurized MDIs, because the high velocity of particle delivery means that about 80% of the dose is deposited on the oropharyngeal mucosa (43) where it is available for uptake into the systemic circulation. Deposition is reduced to about lo-15% if a large-volume spacer is attached to the inhaler (44) . Use of a spacer has been shown to lower the incidence of local steroid side-effects (4547), and it is logical to assume that decreased availability for systemic absorption resulting from lower oropharyngeal deposition would reduce any effects on bone. Using the Turbuhaler@ breath-actuated dry powder delivery system for budesonide results in reduced drug deposition in the mouth (by approximately 60%) compared with the MD1 without a spacer (48) . Thus, differences in systemic side-effects may reflect differences in inhaler technology. This might explain the apparent differences in effects on osteocalcin observed by Brown et al. (17) when using a MD1 with and without a spacer. However, inclusion of a spacer does not always prevent systemic effects, as noted in several studies (7, 16) .
A dry powder inhaler for BDP, the DiskhalerB, has been available for some time and delivers comparable doses to the budesonide Turbuhaler@ (49) . Comparisons of the effects of inhaled corticosteroids on bone using these equivalent devices would help to provide a clearer picture of any differences between BDP and budesonide. To date, only one short-term study of this type in children (35) has been performed. Finally, rinsing the mouth with water after inhalation can remove 80% of the oropharyngeal deposit (45) . Careful attention to inhalation technique can thus help to minimize any adverse systemic effects.
Conclusions
Studies in healthy adult volunteers and asthma patients of various ages have shown that both BDP and budesonide can cause changes in markers of bone turnover, especially osteocalcin, when inhaled at high doses. While these changes are suggestive of bone loss, bone density studies in asthma patients after longterm treatment have produced conflicting results. Inhaled steroids have considerably fewer adverse effects on bone than oral steroids, but the threshold dose at which they begin to affect bone remains unclear. Direct comparisons suggest that budesonide may exert less effect on bone turnover than BDP, but studies with adequate controls for previous corticosteroid use, asthma severity, activity levels and type of inhaler are required to confirm these differences. Prospective, long-term measurements of bone density are also required to establish whether changes in markers of bone turnover translate into an increased risk of osteoporosis and fractures, particularly in patients with increased susceptibility resulting from genetic factors, age or hormonal status.
